Anders Månsson
Fortune : 26 805 $ au 31/05/2026
Fortune : 26 805 $ au 31/05/2026
Anders Månsson is currently Chief Executive Officer & Director at Mr. Månsson Business Development AB, Chief Executive Officer at Iconovo AB since 2025, Chairman at CanImGuide Therapeutics AB since 2017, and Independent Director at EQL Pharma AB since 2022.
Former roles include Chief Executive Officer at LIDDS AB from 2022 to 2023, Chief Business Officer & Deputy CEO at RhoVac AB in 2019, Chief Executive Officer at Phase Holographic Imaging AB from 2024 to 2025, Chief Executive Officer at RhoVac ApS from 2019 to 2025, Chief Executive Officer at Oncoinvent ASA (Old) from 2023 to 2024, Director at Respiratorius AB, Independent Director at Amniotics AB from 2021 to 2022, and Vice President & Head-Global Business Development at LEO Pharma A from 2011 to 2017.
Education includes an undergraduate degree from the University of Lund in 1997 and an MBA from Business School Lausanne in 2007.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
EQL PHARMA AB 0,03% | 31/03/2025 | 10 000 ( 0,03% ) | 26 805 $ | 31/05/2026 |
| Sociétés | Poste | Début |
|---|---|---|
| EQL PHARMA AB | Directeur/Membre du Conseil | 23/08/2018 |
| ICONOVO AB | Directeur Général | 31/10/2025 |
CanImGuide Therapeutics AB
CanImGuide Therapeutics AB Pharmaceuticals: MajorHealth Technology Develops cancer therapies | Président | 01/06/2017 |
Anders Månsson Business Development AB | Directeur Général | - |
| Sociétés | Poste | Fin |
|---|---|---|
RhoVac ApS
RhoVac ApS Pharmaceuticals: MajorHealth Technology Manufactures medicines for cancers | Directeur Général | 01/02/2025 |
| PHASE HOLOGRAPHIC IMAGING PHI AB | Directeur Général | 01/02/2025 |
Oncoinvent AS
Oncoinvent AS Pharmaceuticals: MajorHealth Technology Develops alpha-emitting radiopharmaceuticals for cancer treatment | Directeur Général | 01/09/2024 |
| LIDDS AB | Directeur Général | 01/08/2023 |
| AMNIOTICS AB | Directeur Général | 01/01/2019 |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 14 |
|---|---|
LEO Pharma A/S
LEO Pharma A/S Medical/Nursing ServicesHealth Services Provides dermatology services | Health Services |
University of Lund
University of Lund Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Phase Holographic Imaging AB
Phase Holographic Imaging AB BiotechnologyHealth Technology Develops and manufactures imaging microscopes and cell analyzers | Health Technology |
EQL Pharma AB
EQL Pharma AB Pharmaceuticals: GenericHealth Technology Manufactures and distributes generic and specialty pharmaceutical products | Health Technology |
Respiratorius AB
Respiratorius AB Pharmaceuticals: MajorHealth Technology Develops pharmaceutical drugs to treat chronic obstructive pulmonary disease and asthma | Health Technology |
CanImGuide Therapeutics AB
CanImGuide Therapeutics AB Pharmaceuticals: MajorHealth Technology Develops cancer therapies | Health Technology |
LIDDS AB
LIDDS AB Pharmaceuticals: MajorHealth Technology Focuses on the development of treatment alternatives and hormonal therapy for prostate cancer | Health Technology |
Business School Lausanne
Business School Lausanne Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Oncoinvent AS
Oncoinvent AS Pharmaceuticals: MajorHealth Technology Develops alpha-emitting radiopharmaceuticals for cancer treatment | Health Technology |
Iconovo AB
Iconovo AB Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company that manufactures and wholesales powder-based inhalation drugs and devices | Health Technology |
RhoVac ApS
RhoVac ApS Pharmaceuticals: MajorHealth Technology Manufactures medicines for cancers | Health Technology |
RhoVac AB
RhoVac AB BiotechnologyHealth Technology Engages in the research and development of immunotherapy for therapeutic cancer vaccines | Health Technology |
Amniotics AB
Amniotics AB BiotechnologyHealth Technology Develops stem cell-based therapeutics for the treatment of human diseases | Health Technology |
Anders Månsson Business Development AB |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national